LIQUID-FILLED IMMEDIATE RELEASE SOFT GELATIN CAPSULES
Described herein are oral pharmaceutical compositions comprising labile, air-, moisture-, or heat-sensitive active pharmaceutical ingredients and methods for making the same. In particular, immediate release capsules comprising non-aqueous fills comprising moisture-sensitive active pharmaceutical ingredients are described.
1 . An oral pharmaceutical composition comprising a soft capsule shell comprising an immediate release matrix comprising:
(a) one or more lipid or lipophilic vehicles;
(b) one or more active pharmaceutical ingredients;
(c) one or more pharmaceutically acceptable excipients; and
wherein the one or more active pharmaceutical ingredients are suspended within the matrix and the matrix inhibits moisture from contacting the active pharmaceutical ingredient.
2 . The composition of claim 1 , wherein the one or more active pharmaceutical ingredients comprise moisture-sensitive active ingredients, light-sensitive active ingredients, or a combination thereof.
3 . The composition of claim 1 , wherein the one or more active pharmaceutical ingredients comprise a moisture-sensitive active ingredient.
4 . The composition of claim 3 , wherein the moisture-sensitive active ingredient comprises dabigatran, aspirin, or diclofenac.
5 . The composition of claim 1 , wherein the active pharmaceutical ingredient comprises dabigatran.
6 . The composition of claim 1 , wherein the one or more lipid or lipophilic vehicles comprise about 35% to about 90% of the total mass of the matrix.
7 . The composition of claim 1 , wherein the one or more lipid or lipophilic vehicles comprise soybean oil, fish oil, polyunsaturated fatty acids, Miglyol® 812, Paceol™, or Capryol™, or a combination thereof.
8 . The composition of claim 1 , wherein the one or more active pharmaceutical ingredients comprise about 10% to about 40% of the total mass of the matrix.
9 . The composition of claim 1 , wherein the one or more pharmaceutically acceptable excipients comprise about 0.01% to about 15% of the total mass of the matrix.
10 . The composition of claim 1 , wherein the one or more pharmaceutically acceptable excipients comprises one or more non-ionic surfactants; one or more hydrophilic ionic polymers, one or more hygroscopic polymers, one or more pH buffering agents, one or more neutralizing agents, one or more antioxidants, one or more water-binding excipients, or one or more absorption enhancers, or a combination thereof.
11 . The composition of claim 1 , wherein the one or more pharmaceutically acceptable excipients comprises: antioxidants, non-ionic surfactants, absorption enhancers, or combinations thereof.
12 . The composition of claim 11 , wherein the non-ionic surfactants comprise about 5% to about 15% of the total mass of the matrix.
13 . The composition of claim 11 , wherein the non-ionic surfactants comprise about 35% to about 80% of the total mass of the matrix.
14 . (canceled)
15 . The composition of claim 11 , wherein the one or more antioxidants comprises about 0.01% to about 2% of the total mass of the matrix.
16 . The composition of claim 11 , wherein the one or more antioxidants comprise tocopherol, BHT, BHA, citric acid, ascorbic acid, or phenolic diterpene, or a combination thereof.
17 - 19 . (canceled)
20 . The composition of claim 1 , wherein the soft capsule shell comprises one or more film forming polymers, one or more plasticizers, and one or more solvents.
21 . (canceled)
22 . The composition of claim 1 , wherein the soft capsule shell comprises:
(a) about 43% of one or more film-forming polymers;
(b) about 20% of one or more plasticizers; and
(c) about 37% of one or more solvents.
23 . (canceled)
24 . The composition of claim 1 , wherein the matrix comprises:
(a) about 80% to about 90% soybean oil;
(b) about 9% to about 20% dabigatran; and
(c) about 0.01% BHT.
25 - 30 . (canceled)
31 . A method for manufacturing an oral immediate release soft capsule shell and matrix fill comprising:
(a) providing a matrix comprising:
(i) about 80% to about 90% soybean oil;
(ii) about 9% to about 20% dabigatran; and
(ii) about 0.01% BHT;
(b) providing a soft capsule gel mass comprising:
(i) about 43% of at least one film-forming polymer;
(ii) about 20% of at least one plasticizer; and
(iii) about 37% of a solvent;
(c) casting the soft capsule gel mass into films using heat-controlled drums or surfaces; and
(d) forming a soft capsule comprising the matrix composition using rotary die encapsulation technology.
32 - 35 . (canceled)
36 . A method for treating, ameliorating the symptoms of, or delaying the onset of a medical condition by providing a subject in need thereof with an oral pharmaceutical composition comprising:
(a) one or more lipid or lipophilic vehicles;
(b) one or more light or water sensitive active pharmaceutical ingredients; and
(c) one or more pharmaceutically acceptable excipients;
wherein the one or more active pharmaceutical ingredients are suspended within the matrix fill and the matrix inhibits moisture from contacting the active pharmaceutical ingredients.
37 . The method of claim 36 , wherein the medical condition comprises a coagulation disorder comprising: stroke, ischemic stroke, hemorrhagic stroke, pulmonary embolism, clotting in patients with non-valvular atrial fibrillation, stroke in patients with non-valvular atrial fibrillation, systemic embolism in patients with non-valvular atrial fibrillation, deep vein thrombosis or a combination thereof.
38 - 44 . (canceled)